Novel Agent Reactivates an Immune Call by LIF Blockade
A groundbreaking therapy known as the novel agent reactivates has emerged, offering a dual mechanism of action to effectively eradicate malignant stem cells and stimulate the immune system. Developed by the Vall d'Hebron Institute of Oncology (VHIO), this agent, called MSC-1, acts by inhibiting LIF (Leukemia Inhibitory Factor) and has demonstrated its ability to tackle cancer through two distinct approaches.
In tumors characterized by high levels of LIF, this particular protein fuels the growth of cancer stem cells. However, with the introduction of LIF blockade, these tumor-initiating stem cells are effectively eliminated, impeding the spread of metastatic cells and preventing cancer recurrence.
Furthermore, heightened expression of LIF cripples the body's anti-tumor defense mechanism, disabling the immune system's ability to counteract cancer. By blocking LIF, the therapy reactivates the alarm system responsible for initiating an anti-tumoral immune response.
Joan Seoane, a trailblazer in previous LIF research, along with his team, was the first to establish the correlation between this multifunctional protein and cancer. Their work revealed that LIF blockade not only eradicates cancer stem cells but also halts disease progression and recurrence.
In the present study, Seoane and his team have shed light on LIF's involvement in the immune system's anti-cancer response, further underscoring its significance in the therapeutic landscape.
After years of rigorous research and validating LIF's potential as a therapeutic target using preclinical and experimental models, Joan Seoane founded Mosaic Biomedicals. The company's primary objective is to identify, develop, enhance, and swiftly translate novel therapies to benefit patients at the earliest possible stage.
Through Mosaic Biomedicals, significant progress has been made in advancing the first-in-class MSC-1 LIF inhibitor towards clinical trials. This promising agent is currently undergoing assessment in these trials to facilitate further development and ultimately provide substantial benefits to patients.
